2020, 2019, 2018, 2017, 2016, 2015, 2014, 2013
July – September Revenues amounted to MSEK 738.5 (679.1), corresponding to an increase of +9% for the period.The organic growth1 during the third quarter was +13%. The currency impact in the quarter was 0% while the divestments generated an effect of -4%.EBIT (Operating Profit) amounted to MSEK 99.5 (43.7), corresponding to an increase of 127%.EBITDA1...
April – June Revenues amounted to MSEK 747.9 (688.9), corresponding to an increase of +9% for the period. The organic growth1 during the second quarter was +8%. The currency impact in the quarter was 0% while the acquisitions of the product portfolios Pevaryl® from Johnson & Johnson and Flux®, Decubal®, Apobase®, Lactocare® from Teva generated...
January – March Revenues amounted to MSEK 713.0 (793.6), corresponding to a decrease of -10% for the period. The organic growth* during the first quarter was -16%. The currency impact in the quarter was -1% while the acquisitions of the product portfolios Proct® from Leo Pharma and Pevaryl® from Johnson & Johnson generated growth of...
Today, on 30 March 2021, Karo Pharma is publishing its annual report for 2020 on the company’s website, www.karopharma.com. For further information, please contact: Jon Johnsson, CFO, 073-507 88 61, jon.johnsson@karopharma.com The Annual Report is published in Swedish and English. The Swedish version represents the original version and has been translated into English. This information...
Q4, October – December Net sales amounted to MSEK 721.2 (649.3). This corresponds to an increase of 11% for the period. The organic growth* during the fourth quarter was +1%. The currency impact in the quarter was -1% while the acquisitions of the product portfolios Proct® from Leo Pharma and Pevaryl® from Johnson & Johnson...
